It's one thing when you have a severe disease, but we're still learning, and I think ten years from now it might be a reasonable thing to do
( n = 149,051) showed similar findings for EPA/DHA supplementation, with estimated risk reductions as follows: CVD mortality (0.94 [0.890.99]), non-fatal MI 0.92 [0.851.00]), CHD events 0.94 [0.890.99]) [77]
Self-insured employers are increasingly requiring GLP-1 patients to participate in structured management programs rather than writing blank-check prescriptions, creating an opportunity for Ro to sell HR benefits teams on its combination of brand recognition, vertically integrated care infrastructure, and manufacturer partnerships but also forcing it to prove it can compete on adherence rates & long-term outcomes rather than only access, convenience, and pricing
The steady inclusion of GLP-1s and SGLT2s has directed prescribing practices, away from the longstanding reliance on older, generic drugs
Wegovy interacts with insulin, sulfonylureas, and meglitinides, increasing the risk of hypoglycemia
Recent studies have shed new light on the interaction between AR and miRNAs in various diseases, including prostate cancer, ovarian cancer, and breast cancer, among others[39]